Cellectar Biosciences, Inc. (CLRB)
| Market Cap | 17.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.54M |
| Shares Out | 1.81M |
| EPS (ttm) | -23.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 179,526 |
| Open | 8.55 |
| Previous Close | 8.93 |
| Day's Range | 8.30 - 9.85 |
| 52-Week Range | 6.72 - 94.50 |
| Beta | 0.52 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Aug 12, 2025 |
About CLRB
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 cli... [Read more]
Financial Performance
Financial StatementsNews
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal Models Auger Emitters Offer the Potential Benefit of Enhanced Cytotoxicity, Safety and Ease-of-Use FLORHAM PARK, N.J., June 24, 2...
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for ...
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed: Twice the Reported 2.25 Median In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed:...
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for ...
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
Designation Supported by CLOVER WaM Phase 2 Study Data Which Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA to Determine if CLOVER WaM Phase 2 Data Meets Criteria to Apply for...
Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call Transcript
Cellectar Biosciences Inc. (NASDAQ:CLRB) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Jim Caruso - President and CEO Chad Kolean - CFO Jarrod Longcor - COO Anne Marie...
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializa...
Cellectar Announces Plan to Explore Strategic Alternatives
FLORHAM PARK, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commerciali...
Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript
Cellectar Biosciences Inc. (NASDAQ:CLRB) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Anne Marie Fields – Managing Director-Precision AQ Jim Caruso – President and ...
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a treatment for Waldenström macroglobulinemia (WM)
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025
FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commerciali...
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
FLORHAM PARK, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializ...
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference
Oral Presentation Presented at ASH 2024 Showed Iopofosine I 131 Achieved an 83.6% ORR and Exceeded Primary and Secondary Efficacy Endpoints in Phase 2 CLOVER-WaM Study for Relapsed/Refractory Waldenst...
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options
On Tuesday, Cellectar Biosciences, Inc. CLRB unveiled a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform, which targets cancer.
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)
BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC today announced the signing of a strategic Master Supply Agreement with Cellectar Biosciences, Inc. (NASDAQ: CLRB) under which Celle...
Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2024 Earnings Conference Call November 18, 2024 8:30 AM ET Company Participants Anne Marie Fields - Managing Director, Precision AQ Jim Caruso - President...
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66 th Annual American Society of Hematology Meeting and Exposition
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
NorthStar to provide Cellectar with non-carrier-added Ac-225 for its expanded portfolio of clinical programs
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in 2025 Cellectar broadens global manufacturing network in preparation for potential ...
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializ...
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024
Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q
FLORHAM PARK, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company, announced today it received a letter dated October 31...
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia
Jorge Castillo, M.D. to Present Iopofosine I 131 Activity in Bing-Neel Syndrome Andrei Shustov, M.D.